Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07639008
Starting soon Observational

Epidemiology of Invasive Bacterial Infections in Children With Sickle Cell Disease in France Between 2020 and 2025

NCT07639008 · tracked via the Priya Life Science France tracker
Sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Started
2026-07-15
Last updated
2026-06-10

Condition(s) studied

Sickle Cell Disease (SCD)Invasive Bacterial Infections

Study summary

Children with sickle cell disease are at high risk of invasive bacterial infections, which may lead to serious complications. Preventive measures, including antibiotic prophylaxis and vaccination, have changed the epidemiology of these infections over time. New pneumococcal conjugate vaccines have recently become available, and updated data are needed to better understand which bacteria are currently responsible for invasive infections in this population.

The aim of this retrospective study is to describe the bacterial distribution of invasive bacterial infections in children with sickle cell disease in France between 2020 and 2025. The results may help improve knowledge of these infections and guide future prevention strategies, including antibiotic management and vaccination policies.

Eligibility

Sex
ALL
Min age
—
Max age
17 Years
Healthy volunteers
No
Inclusion Criteria * Children with sickle cell disease aged under 18 years * Hospitalized between January 2020 and December 2025 * Hospitalized for an invasive bacterial infection clinically defined as meningitis, pleuropneumonia, osteoarticular infection, or primary bacteremia * Bacterium identified by culture or PCR Exclusion Criteria * Opposition from the child or his/her parents * Bacterium identified by serology * Urinary tract infection

Primary outcome measure(s)

  • To establish the bacterial distribution of invasive infections in children with sickle cell disease in France (bacteremia, meningitis, osteoarticular or pleural infections) between 2020 and 2025 — During the invasive bacterial infection episode occurring between January 1, 2020 and December 31, 2025
    Proportion of the different bacteria involved in IBIs in children with sickle cell disease

Trial sites (31)

FacilityCityRegionStatus
Hôpital Victor Dupouy (CH Argenteuil) Argenteuil France
CHI Robert Ballanger Aulnay-sous-Bois France
Hôpital Jean Verdier Bondy France
Hôpital Pellegrin - Hôpital des Enfants Bordeaux France
Hôpital Ambroise Paré Boulogne-Billancourt France
Hôpital Saint Camille Bry-sur-Marne France
Hôpital NOVO Cergy-Pontoise France
Hôpital Antoine Béclère Clamart France
CH Sud Francilien Corbeil-Essonnes France
CHI Créteil Créteil France
CH du Sud Seine et Marne Fontainebleau France
CH Gonesse Gonesse France
GHEF, Site de Marne-la-Vallée Jossigny France
Hôpital Bicêtre Le Kremlin-Bicêtre France
GHT Yvelines Nord Mantes-la-Jolie France
Hôpital Nord, AP-HM Marseille France
GHEF, Site de Meaux Meaux France
GH Sud Ile-de-france Melun France
GHI Le Raincy-Montfermeil Montfermeil France
CHU Nantes Nantes France
CH Rives de Seine, Site de Neuilly-sur-Seine Neuilly-sur-Seine France
CHU Lenval Nice France
Hôpital Paris-Saclay Orsay France
Hôpital Necker Paris France
Hôpital Robert Debré Paris France
Hôpital Trousseau Paris France
CHI Poissy Poissy France
CH Rambouillet Rambouillet France
CH Saint Denis, Hôpital Delafontaine Saint-Denis France
Hôpital André Mignot Versailles France
Hôpital Intercommunal Villeneuve-St-Georges Villeneuve-Saint-Georges France

More Assistance Publique - Hôpitaux de Paris trials in France

Fusion Ultrasound for Diagnosis and Monitoring of Endometriosis Lesions Active, not recruiting
neonAtal motoR paTtErn autoMatIc analySis Recruiting
Characterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis Recruiting
Effect of Adding Vasopressin on Cardiac Output, Blood Pressure, Diuresis, and Tissue Perfusion Indices in Patients With Septic Shock Starting soon
Efficacy of Methylprednisolone Pulses in Neuroendocrine Celles Hyperplasia of Infancy : An Early Phase Study Recruiting

Other trials for the same condition

Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients Active, not recruiting
Exploratory Study on Global Reflexology in Sickle Cell Disease Recruiting
Standard of Care Comparative Arm of Phase 1/2 Gene Therapy Trial DREPAMIR" in Severe Sickle Cell Disease Patients Starting soon
Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient Recruiting
Relationship Between Biological Phenotype, Clinical Severity of Sickle Cell Disease, and Blood Coagulation Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07639008 on ClinicalTrials.gov ↗ ← All trials in France